Adar B. Yaacov

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

From matching to facilitation: Reframing AI's role in clinical trial enrollment.

From matching to facilitation: Reframing AI's role in clinical trial enrollment.

Journal: Patterns (New York, N.Y.)

Published: July 15, 2026

CBFB mutations predict endocrine therapy benefit in estrogen receptor-positive breast cancer.

CBFB mutations predict endocrine therapy benefit in estrogen receptor-positive breast cancer.

Journal: medRxiv : the preprint server for health sciences

Published: June 04, 2026

Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study.

Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study.

Journal: Journal of clinical medicine

Published: April 28, 2026

The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC).

The Impact of Minimal Residual Disease (MRD) Testing on the Decision-Making Process in Non-Small-Cell Lung Cancer (NSCLC).

Journal: Cancers

Published: March 16, 2026

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

Journal: ESMO open

Published: February 26, 2026

A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer.

A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer.

Journal: Cancer research communications

Published: February 20, 2026

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20-mutant NSCLC: case report.

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20-mutant NSCLC: case report.

Journal: Frontiers in oncology

Published: February 16, 2026

Consensus Copy-Number Alteration Signatures from Clinical Panels Enable Pan-Cancer Risk Stratification and Therapy Response Association.

Consensus Copy-Number Alteration Signatures from Clinical Panels Enable Pan-Cancer Risk Stratification and Therapy Response Association.

Journal: International journal of molecular sciences

Published: January 18, 2026

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.

Journal: Cells

Published: December 01, 2025

Bronchoalveolar Lavage in Immunocompetent Patients with Pneumonia: A Retrospective Cohort Study Shows No Survival Benefit.

Bronchoalveolar Lavage in Immunocompetent Patients with Pneumonia: A Retrospective Cohort Study Shows No Survival Benefit.

Journal: Journal of clinical medicine

Published: September 25, 2025

Evaluation of PSI, CURB-65, and CRB-65 as prognostic tools in hospitalized immunocompetent patients with pneumonia: real-world outcomes from internal medicine wards.

Evaluation of PSI, CURB-65, and CRB-65 as prognostic tools in hospitalized immunocompetent patients with pneumonia: real-world outcomes from internal medicine wards.

Journal: Pneumonia (Nathan Qld.)

Published: January 15, 2025

Graph convolution networks model identifies and quantifies gene and cancer specific transcriptome signatures of cancer driver events.

Graph convolution networks model identifies and quantifies gene and cancer specific transcriptome signatures of cancer driver events.

Journal: Computers in biology and medicine

Published: May 20, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026